[Myelin Oligodendrocyte Glycoprotein Antibody Associated Disorders].
Journal
Brain and nerve = Shinkei kenkyu no shinpo
ISSN: 1881-6096
Titre abrégé: Brain Nerve
Pays: Japan
ID NLM: 101299709
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
9
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
The antibody against myelin oligodendrocyte glycoprotein (MOG) has been identified for its association with several clinical phenotypes including acute or multiphasic disseminated encephalomyelitis, optic neuritis, NMOSD, and brainstem or cerebral cortical encephalomyelitis, and now generally called MOG associated disorders (MOGAD). Recent brain-biopsied MOG-antibody-positive case reports have suggested the dominance of humoral immunity, and the humoral and cellular immune responses against MOG is elucidated to develop perivenous inflammatory demyelination. In this review, we will focus on the clinical, pathological, and treatment strategies for MOG-antibody-related diseases.
Identifiants
pubmed: 37287354
pii: 1416202406
doi: 10.11477/mf.1416202406
doi:
Substances chimiques
Myelin-Oligodendrocyte Glycoprotein
0
Autoantibodies
0
Types de publication
Review
English Abstract
Journal Article
Langues
jpn
Sous-ensembles de citation
IM